Prevalence and Associated Clinical Factors with Hepatitis B, C,and HIV Infections among Sickle Cell Disease Patients: Evidence from a Tertiary Hospital in Northern Nigeria
Keywords:
Hepatitis B virus, HCV, HIV, Sickle cell disease, ZariaAbstract
Sickle cell disease (SCD) is a prevalent genetic disorder in sub-Saharan Africa, with Nigeria bearing the highest burden. The chronic nature of SCD necessitates frequent medical interventions, including blood transfusions, which heighten the risk of transfusion-transmissible infections like hepatitis B virus (HBV). Despite regional data on HBV prevalence among SCD patients in Nigeria, there is limited information from northern regions such as Zaria. The study assessed the prevalence of hepatitis B and C, and HIV, and also assessed its association with clinical variables including blood transfusion, bone pain crises, and hospitalization among SCD patients in Zaria. A cross-sectional study was conducted at a tertiary health facility in Zaria. A total of 311 SCD patients were enrolled across paediatric, adolescent, and adult age groups. Clinical and demographic data were obtained through structured questionnaires and medical records. Serum samples were screened for HBsAg, HCV and HIV antibodies using rapid diagnostic kits. Statistical analysis was performed using SPSS v25, with significance set at p < 0.05. The median age of participants was 17 years; 65% were female, and 92.9% had HbSS genotype. Only 269 participants submitted samples for screening for HBsAg (5/269 were positive), although the sample size is 311, while all participants tested negative for HCV and HIV. No statistically significant associations were found between HBsAg status and history of blood transfusion (OR: 1.186; p = 0.593), frequency of bone pain crises (OR: 0.977; p = 0.355), or hospitalization (OR: 1.190; p = 0.608). In conclusion, the low HBsAg prevalence and absence of HCV and HIV seropositivity among SCD patients in Zaria may suggest improvements in transfusion safety, vaccination uptake, and infection control. Continued surveillance, enhanced preventive strategies are recommended to sustain these gains
References
1. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality and interventions. Lancet Haematol. 2013;381(9861):142–151.
2. Fasola FA, Otegbayo JA, Abja A. Post-transfusion hepatitis B and C virus infections in sickle cell disease patients in Nigeria. Afr J Med Med Sci. 2004;33(4):333–337.
3. Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of hepatitis B virus infection in Nigeria, 2000–2013: a systematic review and meta-analysis. Niger J Clin Pract. 2015;18(2):163–172.
4. Olatunji PO, Obi GO, Ayoola EA. The risk of transfusion-transmissible hepatitis B and C viruses in blood transfusion in SCD patients. Trop Med Int Health. 2002;7(12):1145–1148.
5. Uadia PO, Kehinde MO, Idogun SE. Hepatitis B surface antigenaemia in sickle cell anaemia patients in Benin City. Ann Trop Pathol. 2023;14(1):7–10.
6. Akpan IS, Onukak AE, Edet IV, Oyewumi AO. The burden of human immunodeficiency virus, hepatitis B and C virus infections in patients with sickle cell anemia in Uyo, Nigeria: A hospital based cross-sectional study. Int J Blood Transfus Immunohematol 2021;11:1-6.
7. Emeribe AU, Eke FN. Hepatitis B surface antigenaemia among sickle cell disease patients in Jos, Nigeria. Niger J Med. 2017;26(2):134–137.
8. Forbi JC, Gabadi S, Alabi R, Iperepolu HO, Zungwe T, Agwale SM. The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte count among Nigerians with HIV infection. J Med Virol. 2007;79(10):1450–6.
9. Okoroiwu HU, Umoh EA, Asanga EE, Edet UO, Atim-Ebim MR, Tangban EA, et al. Thirty-five years (1986–2021) of HIV/AIDS in Nigeria: bibliometric and scoping analysis. AIDS Res Ther. 2022;19:64.
10. Al-Riyami AZ, Al-Huneini M, Al-Maqbali SA, Al-Mammary SS, Daar S. Hepatitis B virus infection in patients with sickle cell disease in Oman: time to revisit prevention strategy. Oman Med J. 2019;34(6):486–490.
11. Osei-Yeboah J, Owiredu WKBA, Norgbe GK, Agyemang-Yeboah F, Lokpo SY. Hepatitis B and C viral infections among sickle cell disease patients in Ghana. J Hematol. 2014;3(1):1–7.
12. National Blood Transfusion Service (NBTS), Nigeria. National Blood Policy. Abuja: Federal Ministry of Health; 2006.
13. Okocha EC, Ibeh CC, Ele PU, Ibeh NC. Hepatitis C virus infection in Nigerians with sickle cell disease. Trop J Med Res. 2005;9(1):16–20.
14. Nwogoh B, Aigberadion U, Ikponmwen D. Prevalence of HIV and hepatitis viruses among sickle cell disease patients in Benin City, Nigeria. Ann Afr Med. 2012;11(3):217–220.
